Low blood carotenoid status in dementia and mild cognitive impairment: A systematic review and meta-analysis

Association between serum carotenoids and migraine in adults: a cross-sectional study from NHANES data

BACKGROUND

Little is known regarding the impact of serum carotenoids, a class of compounds having anti-inflammatory and antioxidant properties, on migraine. This study aimed to examine the association between serum carotenoid levels and migraine risk among United States adults.

METHODS

This cross-sectional study recruited 7744 individuals aged 20 years or older from the National Health and Nutrition Examination Survey conducted between 2001 and 2004. The concentrations of five serum carotenoids (α-carotene, β-carotene, β-cryptoxanthin, lycopene, and lutein + zeaxanthin) and retinol were measured using high-performance liquid chromatography. Migraine was diagnosed when participants reported that they had severe headaches or migraines during the past three months. Weighted multivariable logistic regression and restricted cubic spline models were used to determine the association between serum carotenoid levels and migraine risk.

RESULTS

Among the 7744 participants enrolled in the study, 1595 (20.6%) had migraine. Compared with the lowest quartiles, the highest quartiles of the three serum carotenoids were associated with a lower risk of migraine, with a multivariable-adjusted odds ratio (OR) of 0.74 (95% confidence interval [CI], 0.57-0.97) for α-carotene, 0.64 (95% CI, 0.49-0.83) for β-carotene, and 0.64 (95% CI, 0.53-0.78) for lutein + zeaxanthin, while the third quartile of serum β-cryptoxanthin had lower odds of migraine (OR, 0.70; 95% CI, 0.54-0.90). The U-shaped patterns of nonlinear relationships between serum β-cryptoxanthin and lutein + zeaxanthin levels and migraine risk were represented by restricted cubic splines. No association was observed between serum lycopene and retinol levels and migraine.

CONCLUSIONS

Low serum carotenoid levels were associated with an increased risk of migraine. Further prospective investigations are warranted to clarify the causative relationship and explore the possible prevention and treatment of migraine using carotenoid supplementation.

Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer's Disease

Alzheimer's disease (AD) is characterized by, among other things, dementia and a decline in cognitive performance. In AD, dementia has neurodegenerative features and starts with mild cognitive impairment (MCI). Research indicates that apoptosis and neuronal loss occur in AD, in which oxidative stress plays an important role. Therefore, reducing oxidative stress with antioxidants is a natural strategy to prevent and slow down the progression of AD. Carotenoids are natural pigments commonly found in fruits and vegetables. They include lipophilic carotenes, such as lycopene, α- and β-carotenes, and more polar xanthophylls, for example, lutein, zeaxanthin, canthaxanthin, and β-cryptoxanthin. Carotenoids can cross the blood-brain barrier (BBB) and scavenge free radicals, especially singlet oxygen, which helps prevent the peroxidation of lipids abundant in the brain. As a result, carotenoids have neuroprotective potential. Numerous in vivo and in vitro studies, as well as randomized controlled trials, have mostly confirmed that carotenoids can help prevent neurodegeneration and alleviate cognitive impairment in AD. While carotenoids have not been officially approved as an AD therapy, they are indicated in the diet recommended for AD, including the consumption of products rich in carotenoids. This review summarizes the latest research findings supporting the potential use of carotenoids in preventing and alleviating AD symptoms. A literature review suggests that a diet rich in carotenoids should be promoted to avoid cognitive decline in AD. One of the goals of the food industry should be to encourage the enrichment of food products with functional substances, such as carotenoids, which may reduce the risk of neurodegenerative diseases.

Association between Skin Carotenoid Levels and Cognitive Impairment Screened by Mini-Cog in Patients with Glaucoma

Carotenoids, having strong antioxidant properties, have been associated with neurodegenerative conditions like dementia and glaucoma, characterized by neuronal loss leading to cognitive and visual dysfunction. Therefore, carotenoids have attracted attention as factors predictive of the onset and progression of these neurodegenerative diseases. However, the impact of carotenoids on cognitive impairment and glaucomatous visual field defects remains unexplored. We conducted a retrospective, observational clinical study to investigate the association between skin carotenoid (SC) levels and cognitive impairment, as screened by the Mini-Cog test, in glaucoma patients. The study included 406 participants and 812 eyes were examined (average age: 69.7 ± 11.4 years; 228 men, 178 women) with various types of glaucoma: primary open angle (57.6%), exfoliation (18.6%), and other types (23.8%). SC levels were estimated via pressure-mediated reflection spectroscopy. Mixed-effects regression models were utilized to examine the relationship between SC levels, visual field defects, and Mini-Cog results. Of the participants, 28 (6.9%) tested positive on the Mini-Cog, suggesting cognitive impairment. The average SC level in the Mini-Cog positive group was significantly lower than in the negative group (269.5 ± 86.4 A.U. vs. 329.2 ± 120.4 A.U., respectively; p = 0.01). Additionally, the visual field mean deviation (MD) in the Mini-Cog positive group was notably worse than that in the negative group (-19.64 ± 9.07 dB vs. -12.46 ± 9.28 dB, respectively; p < 0.0001). The mixed-effects regression analysis revealed a significant association between Mini-Cog positivity and lower SC levels (p = 0.0006), although SC levels did not significantly correlate with MD (p = 0.3). Our findings suggest that cognitive impairment in glaucoma patients is associated with lower SC levels, underscoring the potential benefits of maintaining carotenoid levels to slow cognitive function decline. The protective role of carotenoids in glaucoma merits further investigation.

Alzheimer, Parkinson, dementia, and phytochemicals: insight review

Alzheimer's, Parkinson's, and dementia are the leading neurodegenerative diseases that threaten the world with the aging population. Although the pathophysiology of each disease is unique, the steps to be taken to prevent diseases are similar. One of the changes that a person can make alone is to gain the habit of an antioxidant-rich diet. Phytochemicals known for their antioxidant properties have been reported to prevent neurodegenerative diseases in various studies. Phytochemicals with similar chemical structures are grouped. Accordingly, there are two main groups of phytochemicals, flavonoid and non-flavonoid. Various in vitro and in vivo studies on phytochemicals have proven neuroprotective effects by increasing cognitive function with their anti-inflammatory and antioxidant mechanisms. The purpose of this review is to summarize the in vitro and in vivo studies on phytochemicals with neuroprotective effects and to provide insight.